



Dear IgG4-RD Community,

We are pleased to share that Zenas BioPharma has announced positive results from the Phase 3 INDIGO registrational trial for adults living with IgG4-RD.

The highly statistically significant results of the INDIGO trial, the largest clinical trial conducted in patients living with IgG4-RD to date, represents an important development for patients living with IgG4-RD. We would like to express our sincere gratitude to the people living with IgG4-RD, their caregivers and families, and the health care providers, whose collective efforts made this clinical trial possible. We also want to thank the broader IgG4-RD community and the advocacy groups for their on-going support and commitment to those impacted by this disease.

Zenas plans to submit a Biologics License Application to the U.S. Food and Drug Administration (FDA) in the second quarter of 2026. Zenas also intends to submit a Marketing Authorization Application to the European Medicines Agency (EMA) in the second half of 2026.

The Zenas team is dedicated to working alongside this community and the regulatory authorities on next steps to deliver a potential new treatment for patients living with IgG4-RD and we look forward to keeping you updated. Should you have any questions, we encourage you to speak with your healthcare provider about your treatment options and we will continue to provide information as it becomes available.

Sincerely,
The Zenas Team